-
On April 8, 2009, the fda approved the use of Coartem® tablets in the treatment of acute, uncomplicated malaria in adults and in children weighing at least 5 kg. Coartem® tablets contain 20 mg artemether and 120 mg lumefantrine, each of which is a blood schizonticide but with dissimilar modes of action.
-
A recent case of a 17-year-old presenting with acute psychiatric symptoms and possible meningoencephalitis prompted examination of this review article on Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infection (PANDAS).
-
In this issue: Comparing blood pressure medications, determining optimal length of androgen-deprivation therapy, red yeast rice for LDL reduction, and FDA Actions.
-
-
During the 11th Conference of the International Society of Travel Medicine held in Budapest, Hungary, from May 24-28, 2009, the symposium titled "Update: WHO, CDC & Yellow Fever Issues," included a session from Dr. David Hill from National Travel Health Network and Centre (NaTHNaC) titled "Defining Yellow Fever (YF) Risk in Endemic Areas."
-
Several European countries recently have revised their malaria prevention guidelines for travel to India in view of a perceived declining malaria risk. However, it is not clear if the data presented are robust, and further study should address this topic before guidelines are changed.
-
-
Somalia, ravaged by civil unrest for most of the past two decades, is striving to upgrade its health care. Since 2005, national policy has been that rural health posts should use sulfadoxine-pyrimethamine (SP) for presumptive first-line treatment of malaria; established health centers should use either a rapid diagnostic test or microscopy for diagnosis, and then the combination of artesunate and SP to treat confirmed cases of malaria.
-
In this issue: Comparing blood pressure medications, determining optimal length of androgen-deprivation therapy, red yeast rice for LDL reduction, and FDA Actions.
-
In 2003, Burns and colleagues published a cochrane review of available studies examining the effects of early direct extubation to non-invasive ventilation (NIV) in adult patients receiving invasive mechanical ventilation for acute respiratory failure.
